TITLE

Risk Factors for Relapse and Acquired Rifamycin Resistance after Directly Observed Tuberculosis Treatment: A Comparison by HIV Serostatus and Rifamycin Use

AUTHOR(S)
Nettles, Richard E.; Mazo, Dana; Alwood, Karla; Gachuhi, Regina; Maltas, Gina; Wendel, Karen; Cronin, Wendy; Hooper, Nancy; Bishai, William; Sterling, Timothy R.
PUB. DATE
March 2004
SOURCE
Clinical Infectious Diseases;3/1/2004, Vol. 38 Issue 5, p731
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
We sought to determine the risk of acquired rifamycin resistant (ARR) tuberculosis associated with rifampinversus rifabutin-based directly observed therapy and to assess the risk factors for relapse of tuberculosis. This observational cohort study included patients with culture-confirmed rifamycin-susceptible tuberculosis reported to the Baltimore City Health Department (Baltimore, MD) during the period of January 1993 through December 2001. Of the 407 patients, 108 (27%) were human immunodeficiency virus (HIV) seropositive, 161 (40%) were HIV seronegative, and 138 (34%) had an unknown serostatus. Three (2.8%) of 108 HIV-seropositive persons had ARR tuberculosis, compared with 0 of 299 persons with negative or unknown HIV serostatus (P = .02). Among HIV-seropositive patients, 3 (3.7%) of 81 who were treated with rifampin and 0 of 27 who were treated with rifabutin had ARR tuberculosis (P = .57). Among HIV-seropositive patients, the only risk factor for recurrent tuberculosis was a low median initial CD4+ T lymphocyte count (51 vs. 138 cells/mm³; P = .02). The median CD4+ T lymphocyte count among patients with ARR tuberculosis was 51 cells/mm³. ARR tuberculosis can occur with rifampin-based regimens, but in this study, the risk was not significantly higher than that for a rifabutin-based regimen.
ACCESSION #
12354129

 

Related Articles

  • Coinfección de tuberculosis pleural con el virus de inmunodeficiencia humana y sida. González, Joaquín López; Rodríguez, Haidee Marrero; Reyes, Ilena Silva; García, Marelis Veranes; Rodríguez, Liané Benítez // MEDISAN;2013, Vol. 17 Issue 11, p8111 

    The case report of a 19 year-old patient is presented. He had been admitted in Cienfuegos province under the diagnosis of pleural parapneumonic effusion, for which wide spectrum antibiotics were administered which produced him a mild clinical improvement, so he was discharged. Due to the...

  • Substitution of Rifapentine for Rifampin During Intensive Phase Treatment of Pulmonary Tuberculosis: Study 29 of the Tuberculosis Trials Consortium. Dorman, Susan E.; Goldberg, Stefan; Stout, Jason E.; Muzanyi, Grace; Johnson, John L.; Weiner, Marc; Bozeman, Lorna; Heilig, Charles M.; Feng, Pei-Jean; Moro, Ruth; Narita, Masahiro; Nahid, Payam; Ray, Susan; Bates, Edward; Haile, Betial; Nuermberger, Eric L.; Vernon, Andrew; Schluger, Neil W. // Journal of Infectious Diseases;Oct2012, Vol. 206 Issue 7, p1030 

    Background. Rifapentine administered 5 days per week has potent activity in mouse models of antituberculosis chemotherapy, but efficacy and safety data are limited in humans. We compared the antimicrobial activity and safety of rifapentine vs rifampin during the first 8 weeks of pulmonary...

  • TB drug hope.  // New Scientist;6/18/2005, Vol. 186 Issue 2504, p5 

    The article informs that a public-private partnership (PPP) called the TB Alliance has started clinical trials of PA-824, a promising tuberculosis (TB) drug. It follows a major development in the fight against malaria last October when another PPP, the Malaria Vaccine Initiative, announced the...

  • Antibiotic-resistant Campylobacter: an increasing problem. Kent, A J; Farouk, L; Main, J; Hoare, J M // Postgraduate Medical Journal;Feb2008, Vol. 84 Issue 988, p106 

    The case is described of a 27-year-old woman who presented with an acute diarrhoeal illness. She was initially poorly responsive to antibiotics and developed lymphocytic ascites. Diagnosis was difficult to establish, and peritoneal tuberculosis was considered to be the most likely cause of her...

  • Unfashionably Late. Lukela, Michael; DeGuzman, David; Weinberger, Steven; Saint, Sanjay // New England Journal of Medicine;1/6/2005, Vol. 352 Issue 1, p64 

    Presents the clinical problem-solving feature. Case of an 18-year-old man with shortness of breath, a productive cough and a two-week history of pleuritic chest pain; Additional symptoms including night sweats and weight loss; Medical history of the patient; Physical examination and the...

  • The open-air treatment of surgical tuberculosis.  // BMJ: British Medical Journal (International Edition);9/6/2003, Vol. 327 Issue 7414, p560 

    The profound and far-reaching effects of what is popularly known as the open-air treatment of consumption are only just beginning to be appreciated. Having originated merely with an attempt to cure or alleviate a disease which afflicts every race of mankind, it has directed attention to the...

  • New Drug Combo Could Speed TB Treatment: U.S. Study.  // Clinical Infectious Diseases;11/15/2007, Vol. 45 Issue 10, piii 

    The article cites a study from the U.S. that reported on the ability of a drug combination to accelerate treatment of tuberculosis (TB). Researchers found that adding a new antibiotic to the standard mix of drugs used to treat TB could shorten the grueling six-month regimen. By substituting the...

  • In Vitro Efficacy of Fusidic Acid on Drug Resistant Strains of Mycobacterium Tuberculosis. Öztaş, Selahattin; Kurutepe, Melahat; Adıgüzel, Nalan; Acartürk, Eylem; Saraç, Sema; Maraşlı, Dida; Tümer, Özlen; Hazar, Armağan // Turk Toraks Dergisi / Turkish Thoracic Journal;Sep2008, Vol. 9 Issue 3, p109 

    Introduction: We aimed to investigate the in vitro efficacy of fusidic acid (FA) on tuberculosis strains resistant to antituberculous drugs . Material and Method: In our single center, prospective, randomized controlled study, we researched the efficacy of sodium fucidate on tuberculosis bacilli...

  • New Antibiotic for TB? Stephenson, Joan // JAMA: Journal of the American Medical Association;1/19/2005, Vol. 293 Issue 3, p286 

    Reports that a new antibiotic shows promise for treating tuberculosis (TB) more swiftly than current TB drugs. Research conducted by scientists in Belgium, France, Sweden, and the U.S.; How the drug belongs to a family of compounds called diarylquinolines, and appears to have a mechanism of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics